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Abstract: Development of multifunctional nanomaterials, one of the most interesting and 
advanced research areas in the field of nanotechnology, is anticipated to revolutionize cancer 
diagnosis and treatment. Gold nanoparticles (AuNPs) are now being widely utilized in bio-
imaging and phototherapy due to their tunable and highly sensitive optical and electronic 
properties (the surface plasmon resonance). As a new concept, termed “theranostics,” mul-
tifunctional AuNPs may contain diagnostic and therapeutic functions that can be integrated 
into one system, thereby simultaneously facilitating diagnosis and therapy and monitoring 
therapeutic responses. In this review, the important properties of AuNPs relevant to diagnostic 
and phototherapeutic applications such as structure, shape, optics, and surface chemistry are 
described. Barriers for translational development of theranostic AuNPs and recent advances 
in the application of AuNPs for cancer diagnosis, photothermal, and photodynamic therapy 
are discussed.
Keywords: multifunctional gold nanoparticles, cancer bioimaging, cancer photothermal and 
photodynamic therapy
Introduction
Cancer, one of the leading causes of mortality worldwide, has caused approximately 
8.8 million deaths in 2015 (www.who.int). The number of people who are diagnosed 
with this malignancy is expected to rise to 22 million annually in the next 2 decades 
(www.who.int). Despite the increased knowledge about the causes of cancer and the 
improved interventions to prevent and manage the disease, survival rates are still low 
mainly due to the delay in diagnosis, lack of effective therapeutics, and high incidence 
of relapse.
As an emerging concept that facilitates simultaneous diagnosis and treatment, the 
implementation of theranostic nanomaterials (ie, metal and silica nanoparticles [NPs], 
liposomes, dendrimers, quantum dots, and carbon nanotubes) has great potential 
for improved cancer treatment and reduced side effects.1–6 Among these, gold NPs 
(AuNPs) exhibit favorable physical properties and tailored surface functionaliza-
tion, providing a potential platform for developing cancer theranostics. This review 
provides a comprehensive overview of AuNPs as emerging nanomaterials for future 
cancer theranostics. In this regard, the key physicochemical properties of AuNPs 
such as structure, shape, optics, and surface chemistry are discussed. In addition, 
various AuNP-based diagnostic and phototherapeutic strategies under investigation 
are critically evaluated, with a particular emphasis on those developed to overcome 
delivery barriers.
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Key properties of AuNPs for 
diagnosis and phototherapy
Types of AuNPs
Colloidal AuNPs were first produced in 1857 by Faraday,7 
where the “fine particles” were formed from the reduc-
tion of gold chloride by phosphorus and the stabilization 
of AuNPs by carbon disulfide. In 1951, Turkevich et al8 
reported the formation of colloidal AuNPs using triso-
dium citrate (HOC(COONa)(CH
2
COONa)
2
) to reduce 
tetrachloroauric acid (gold [III] chloride [HAuCl
4
]) in 
water, and later Frens9 improved the formation using a 
slightly modified method. Recently, AuNPs have been pro-
duced with various sizes and shapes (ie, gold nanospheres, 
nanorods, nanocages, nanoshells, and nanostars), which 
are dependent upon the synthetic methods adopted for their 
preparation (Figure 1; a summary of synthetic approaches 
to obtain various gold nanostructures has been described 
previously).10–14
Figure 1 Development of theranostic AuNPs in the treatment of cancer.
Notes: (A) Commonly used AuNPs can be categorized depending on the particle shape, including Au nanospheres, nanorods, nanoshells, and nanocages. These AuNPs 
with tunable optical and electronic properties and easy surface functionalizations have presented great potential for cancer bioimaging, PTT/PDT, and targeted drug delivery. 
(B) Functional components including stealth coating materials, bioresponsive moieties, bioactive targeting ligands, bioimaging agents, and therapeutic cargos can be integrated 
into one system, to achieve multifunctional AuNPs for future cancer treatment.
Abbreviations: AuNPs, gold nanoparticles; ePR, enhanced penetration and retention; NIR, near-infrared; PDT, photodynamic therapy; PeG, polyethylene glycol; PTT, 
photothermal therapy.
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Gold nanospheres
Gold nanospheres (particle size 2–100 nm) are generally 
prepared after reducing HAuCl
4
 with the assistance of differ-
ent reducing agents under various temperature and pressure. 
Trisodium citrate (sometimes referred to simply as sodium 
citrate), for example, is a commonly used reducing and sta-
bilizing agent, which is capable of generating monodisperse 
gold nanospheres with different particle sizes by adjusting 
the concentration of citrate.11
The seeding growth strategy has been used to improve 
monodispersity and avoid the formation of large AuNPs 
with irregular shapes (diameter .50 nm), whereby large 
spherical AuNPs are produced by reducing HAuCl
4
 or Au 
(III)-surfactant complexes onto the surface of preexist-
ing seeds using reducing agents such as hydroxylamine 
hydrochloride,15,16 ascorbic acid,17 2-mercaptosuccinic acid,18 
hydroquinone,19 and hydrogen peroxide.20
Gold nanorods (GNRs)
GNRs were first synthesized by Foss et al,21 Martin,22 and 
Perez-Juste et al23 using the template method. They are 
generally synthesized with a size ranging from 10 nm to 
100 nm and an aspect ratio between 1 (sphere) and 7 with a 
corresponding longitudinal plasmon of ~1,050 nm. However, 
the yield is low due to the fact that only one monolayer of 
nanorods is produced using the template approach.
Alternatively, the seed growth method is also used to 
synthesize GNRs.23 In this method, gold seeds are prepared by 
reducing the gold salt with a strong reducing agent (ie, sodium 
borohydride). These seeds that provide the nucleation sites 
are subsequently added to the aqueous surfactant media 
containing the gold salt and the reducing agents (ie, ascorbic 
acid and hexadecyltrimethylammonium bromide [CTAB]) 
for the growth steps.24,25 Additional nucleation during the 
growth stage can be inhibited by controlling the growth 
conditions such as 1) the rate of addition of reducing agents 
to the gold seed and gold salt solution and 2) the reduction 
potential of reducing agents. As a result, the aspect ratios 
of nanorods (the ratio of the longer side to the shorter side) 
can be controlled by using different amounts of gold seeds 
relative to the precursor.
Gold nanocages
Gold nanocages are hollow nanostructures (particle size 
~40–50 nm) which can be prepared with controllable pores 
on the surface via the galvanic replacement reaction between 
truncated silver (Ag) nanocubes and HAuCl
4
.26 Silver nano-
structures with controlled shapes can be generated via the 
polyol reduction, where AgNO
3
 is reduced by ethylene glycol 
to generate Ag atoms followed by nanocrystals or seeds. 
Silver nanostructures are utilized as the sacrificial template 
and can be transformed into AuNPs with hollow structures 
via the galvanic replacement.26 The molar ratio of Ag to 
HAuCl
4
 can be regulated to manipulate the diameter and 
wall thickness of resultant gold nanocages.26
Gold nanoshells
Gold nanoshells are normally composed of dielectric core 
materials (ie, silica and polystyrene) coated by a thin gold 
layer. Core materials such as silica and polystyrene have been 
widely used to provide high stability and monodispersity.27 
These core materials can be tailored by varying the dimen-
sions of the core and/or the shell; normally, the core has a 
diameter ~100 nm and a thin shell of gold about several 
nanometers (~1–20 nm).28,29
Modification of the core surface with a bifunctional ligand 
that enhances the shell coverage is a common method for the 
preparation of gold nanoshells. In the case of silica, the core 
surface is modified by 3-aminopropyltriethoxysilane (APS) 
with both ethoxy and amine groups. The ethoxy group binds 
covalently to silica surface through the hydroxyl group, 
while the amine group attaches to gold seeds. In addition, 
bifunctional linkers such as 3-aminopropyltrimethoxysilane 
(APTMS) and 3-mercaptopropyltrimethoxysilane (MPTMS) 
have also been used to modify the silica, leading to amino- 
and thiol-functionalized surfaces that can efficiently attach 
to gold seeds. As a result, the complete shell is formed by 
aging the gold attached onto the silica core.30
Optical characteristics of AuNPs
It is known that the oscillating electromagnetic field of light 
induces a collective coherent oscillation of the free electrons 
(also known as conduction band electrons) of the metal.31 
The amplitude of the oscillation that reaches a maximum at 
a specific frequency is termed the surface plasmon resonance 
(SPR).31 A strong absorption of the incident light is induced 
by the SPR and can be measured using an ultraviolet (UV)–
visible absorption spectrometer.32 The SPR band of noble 
metals (ie, gold and silver) is known to be much stronger 
than other metals.32 The SPR wavelength of AuNPs can be 
tuned from the visible to the near-infrared (NIR) region by 
changing the size, shape, and structure of AuNPs, as theoreti-
cally described by the Mie theory.32
Two main processes, namely, absorption and scattering, 
occur when the light passes through matter resulting in the 
energy loss of electromagnetic wave.33 The scattered light 
has the same frequency as the incident light (it is termed as 
Rayleigh scattering) or a shifted frequency (it is termed as 
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Raman scattering).33 AuNPs can significantly enhance the 
light scattering, ie, five- to six-fold stronger than most 
strongly absorbing organic dyes and higher than the emission 
of most strongly fluoresceins,34 which makes AuNPs very 
promising imaging and detection platforms for cancer, as 
described in the “AuNPs for cancer diagnosis” section.
The scattering properties are highly dependent on the 
size and shape of AuNPs, which are given in the following 
sections.
Particle size
AuNPs with particle sizes of ~40 nm may be easily detected 
down to a particle concentration of 10-14 M.35,36 Moreover, 
the scattering of ~60 nm AuNPs is ~100-fold stronger than 
the emission of a fluorescein.36 Likewise, ~70 nm AuNPs 
can scatter orders of magnitude stronger than that of a 
polystyrene sphere of the same size.37 It has been reported 
that ~30–100 nm AuNPs can be detected under a micro-
scope using dark-field illumination conditions (only the 
light scattered from indirect illumination of the sample is 
detected).38 Recently, Jain et al34 and Lee and El-Sayed39 
have substantially studied the relationship between the 
optical absorption/scattering and the size of AuNPs using 
the Mie theory. They reported that the total extinction 
of ~20 nm AuNPs was mostly contributed by absorption; 
when the particle size of AuNPs was ~40 nm, they initi-
ated scattering, and when the particle size was ~80 nm, the 
extinction of AuNPs was contributed by absorption and 
scattering in a very similar degree.34,39 This fact that the 
ratio of scattering to absorption increases significantly for 
larger size of particles can guide the development of AuNPs 
for bioimaging.
Particle shape
The optical properties of AuNPs can also be tuned by 
shape.40–42 When the shape of AuNPs is changed from sphere 
to rod, the SPR will be split into two bands, namely, a strong 
band in the NIR region and a weak band in the visible region, 
as predicted by the Gans theory. The strong band, also referred 
to as the longitudinal band, results from electron oscillations 
along the long axis. The weak band, also known as the 
transverse band, is similar to the wavelength of gold nano-
spheres. Tong et al43 reported that the longitudinal band of 
GNRs was red shifted largely by increasing the aspect ratios 
(length/width), which causes the color change from blue to 
red. In addition, Lee and El-Sayed44 have shown that when 
the aspect ratio of GNRs was increased, light scattering was 
significantly enhanced.
It is known that the SPR of gold nanocages may be tuned 
to the NIR region with specified wavelengths.45 For instance, 
the particle size of gold nanocages is generally ~50 nm edge 
width with several nanometer walls and holes for an SPR 
wavelength of ~800 nm.46
Particle composition
It is known that the composition of NPs (particularly semi-
conductor NPs such as quantum dots) is also able to affect the 
scattering properties;47 recently, several studies have focused 
on the scattering properties dependent on the composition of 
Au nanocomplexes.48–50 Jain et al34 have investigated the scat-
tering properties of the core–shell composition in silica–Au 
nanoshells using Mie theory and discrete dipole approxima-
tion method. Results show that the thicknesses of the core 
and the shell and the radius ratio of core/shell significantly 
influenced the optical characteristics such as the resonance 
wavelength, the extinction cross-section, and the ratio of 
scattering to absorption.34 In addition, it was reported that 
the SPR wavelength of silica–Au nanoshells may be changed 
by controlling the Au shell thickness; for example, when 
the shell thickness was decreased from 20 to 5 nm, the SPR 
was red shifted ~300 nm, which most likely results from the 
increased coupling between the inner and outer shell surface 
plasmons for thinner shell particles.30
Surface functionalization of AuNPs
The surface chemistry of gold makes AuNPs a promising 
platform for biomedical applications (Figure 1).11 Brust 
et al51 exploited the high affinity of thiol for gold to produce 
AuNP-thiolates (Au-S); this was achieved using HAuCl
4
, 
thiol, tetraoctylammonium bromide, and NaBH
4
 in water–
toluene and was stabilized via Au-S-stabilizer bonds. These 
NPs were dispersed in organic solvent and required further 
phase transfer or ligand exchange to transfer them into water. 
An essential purification step to remove impurities for use in 
biological application was also necessary.
In addition, ligands containing amine and phosphine 
groups, which also have high affinity with the surface 
of gold, have been used as efficient stabilizing agents.52 For 
example, cationic surfactant-free AuNPs (~2–200 nm) have 
been developed that were synthesized in water using a seed 
growth method, in the presence of l-cysteine methyl ester 
hydrochloride (HSCH
2
CH(NH
2
)COOCH
3
⋅HCl) as a capping 
agent.53 Furthermore, Chhour et al54 have functionalized 
AuNPs using a group of thiol and amine ligands, including 
11-mercaptoundecanoic acid (11-MUDA), 16-mercapto-
hexadecanoic acid (16-MHDA), polyethylenimine (PEI), 
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4-mercapto-1-butanol (4-MB), and 11-mercaptoundecyl-
tetra (ethylene glycol) (MTEG). These ligands enhanced the 
AuNP stability and provided different surface functionalities 
which can influence cell uptake and cytotoxicity.54 Among 
them, the 11-MUDA AuNPs were used to monitor the 
recruitment of monocytes into atherosclerotic plaques in a 
disease mouse model using X-ray computed tomography 
(CT), potentially allowing detection of monocyte recruitment 
in the presence of emerging atherosclerosis therapies.54 In 
addition, Liu et al55 have recently stabilized AuNPs using 
thiol-polyethylene glycol (SH-PEG) at two different ratios 
of thiol to PEG (1:1 and 1:2), significantly improving the 
AuNP stability in biological media. When AuNPs with 
higher PEG content were intravenously injected, they were 
found to accumulate in the liver at a lower level relative to 
counterparts with lower PEG content.55 These results sug-
gest that when designing AuNPs, a rational ratio between 
the anchoring group (ie, thiol) and the hydrophilic group 
(ie, PEG) should be carefully considered, this is important 
for integrating the properties of NPs in certain bio-related 
application.
Targeting ligands56–60 may be modified onto the AuNP 
surface to specifically deliver therapeutic cargos into tissues 
and organs. Recently, tumor-targeted mesoporous silica-
encapsulated GNRs (GNRs@mSiO
2
) for chemotherapy and 
photothermal therapy (PTT) have been developed by Shen 
et al.61 In this study, RGD peptides, a targeting ligand for α
v
β
3
 
integrin receptors that are known to overexpress on several 
cancer cells, were conjugated to the terminal groups of PEG 
on GNRs@mSiO
2
 (namely, pGNRs@mSiO
2
-RGD). The 
pGNRs@mSiO
2
-RGD presented significant stability in bio-
environments and efficient loading of doxorubicin (DOX, an 
antitumor chemotherapeutics). Following the NIR irradiation, 
the combination of photothermal ablation and DOX-mediated 
cytotoxicity using pGNRs@mSiO
2
-RGD resulted in signifi-
cant tumor reduction in subcutaneous xenografted mice.61 
In addition, it has been reported that PEI-capped AuNPs 
(Au-PEI) were conjugated with anisamide (AA, which 
is known to bind to the sigma receptor overexpressed on 
prostate cancer cells)62,63 to produce the AA-targeted AuNPs 
(Au-PEI-AA).59 As a result, Au-PEI-AA facilitated siRNA 
uptake into prostate cancer PC-3 cells via binding to the 
sigma receptor and achieved efficient downregulation of the 
targeted oncogene.59
In addition to the aforementioned stabilizing and target-
ing ligands, the gold surface can also be modified using 
several suitable imaging agents, photosensitive molecules, 
and bioactive/bioresponsive moieties (ie, pH-sensitive 
linkers, matrix metalloproteinase [MMP]-sensitive linkers, 
temperature-sensitive linkers, fusogenic/synthetic peptides, 
and endosomal membrane-disruptive materials) to achieve 
multifunctional AuNPs for cancer diagnosis and photother-
apy, which are discussed in the following sections.
AuNPs for cancer diagnosis
Spectroscopic cancer imaging
For wavelengths .650 and ,2,000 nm, the tissue absorp-
tion is weak, so the NIR light (wavelength from 700 to 
2,500 nm) is normally chosen to image tumor deeply 
within the body. It is worth noting that the penetration 
depth of NIR light into tissues is highly dependent on the 
tissue type, the wavelength, and the condition of the inci-
dent beam (ie, the laser power, irradiation time, and time 
interval).64–66 For example, it was shown that no penetration 
was found in the skin, skull, or brain for NIR light with 
low-power laser; however, 0.45%–2.90% of 810 nm NIR 
light at high power (10–15 W) was delivered into 3 cm of 
the aforementioned tissues.66
AuNPs on their own may act as an NIR-active imaging 
probe for cancer detection facilitating whole-body scans 
due to the unique optical properties. The use of targeted 
AuNPs as the contrast agent was demonstrated by Sokolov 
et al,37 where AuNPs were conjugated with an antibody 
against the epidermal growth factor receptor (EGFR, it 
is known to overexpress on many cancers). These AuNP 
conjugates were used for detecting cancer cells using a 
scanning confocal microscope in the reflectance mode with 
a 647 nm laser to excite the SPR of AuNPs; as a result, 
cells with AuNP conjugates were clearly imaged on a dark 
background.37 El-Sayed et al67 improved the use of AuNPs 
(~35 nm) as the contrast agent via dark-field microscopy. 
Following excitation by white light, only the wavelength of 
light corresponding to the maximum of the SPR of AuNPs 
was displayed intensely, where a bright image of cells with 
AuNPs could be seen on a dark background.67 Moreover, 
cetuximab (CET, a chimeric monoclonal antibody against 
the EGFR)-conjugated PEGylated GNRs (CET-pGNRs) 
was developed for cancer imaging in xenografted mice.68 
The results of in vivo NIR absorption imaging show that 
specific targeting of CET-pGNRs to the tumor region was 
evident by a significant increase in the absorption signal. The 
biodistribution data also show that the amount of AuNPs 
in tumor tissues from mice injected with CET-pGNRs was 
eightfold greater than that recorded by nontargeted pGNRs, 
confirming the results from the NIR absorption imaging. 
These indicate that CET-pGNRs can specifically target tumor 
 
In
te
rn
at
io
na
l J
ou
rn
al
 o
f N
an
om
ed
ici
ne
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
14
3.
23
9.
10
2.
11
3 
on
 2
1-
Se
p-
20
17
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
International Journal of Nanomedicine 2017:12submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
6136
Guo et al
tissues with high specificity and provide a potential tool for 
NIR-based cancer diagnosis.
Recently, the photoacoustic imaging has taken advantage 
of plasmonic systems, such as AuNPs with various sizes 
and shapes.69 Plasmon resonances of AuNPs can be tuned 
to enhance the optical response,70,71 which can give rise to 
heat conversion with high efficiency and to the subsequent 
pressure wave generating the photoacoustic signal. Indeed, 
these properties have been utilized to develop AuNPs as 
contrast agents for the photoacoustic imaging.72 Recently, 
an amphiphilic GNR coated with PEG and poly(lactic-co-
glycolic acid) (PLGA; AuNR⋅PEG⋅PLGA) was developed 
for the photoacoustic imaging in xenografted mice.73 The 
AuNR⋅PEG⋅PLGA could self-assemble into vesicles with 
the AuNRs embedded in the shell formed by the PLGA and 
PEG extending into the aqueous environments to stabilize the 
structure. Furthermore, the in vivo two-dimensional (2D) and 
three-dimensional (3D) photoacoustic images show that the 
strong plasmonic coupling of GNRs in the vesicles induced 
a high photothermal effect and a photoacoustic signal, which 
may potentially be used for image-guided phototherapy in 
the future.73
In addition, AuNPs have also been utilized as high-
quality CT imaging agents due to better X-ray attenuation 
properties (atomic number Z =79; k-edge value =80.7 keV) 
than that of iodinated CT contrast agents.74,75 In addition, 
the conventional small-molecular CT contrast agents are 
rapidly cleared by the kidney resulting in short imaging 
times, whereas the gold surface can be modified with 
biological stabilizing groups (ie, PEG) to improve the 
pharmacokinetic properties,76 which is beneficial for cancer 
imaging. Recently, a folic acid (FA)-targeted gold nano-
sphere (FA-PEG-PEI-AuNPs) was developed using PEI 
and PEG as stabilizing ligands.77 The intravenous injec-
tion of FA-PEG-PEI-AuNPs into an overexpressed folate 
receptor tumor model resulted in significantly higher CT 
values in the tumor region compared with nontargeted 
PEG-PEI-AuNPs. In addition to the “enhanced penetration 
and retention” (EPR)-based passive tumor targeting, the 
FA-mediated active targeting was also able to significantly 
enhance the AuNP accumulation in tumor tissues, resulting 
in enhanced cancer CT imaging.
In addition, AuNPs are also known to enhance the Raman 
scattering signal of adjacent molecules, and therefore, 
surface-enhanced Raman spectroscopy (SERS) imaging 
aided by gold nanomaterials (spheres, rods, cubes, etc.) 
has also widely been used in the detection of viruses and 
cancer cells.78,79
Functionalized imaging agents for cancer 
detection
Hybrid dual imaging technologies, including positron 
emission tomography (PET)/CT, PET/magnetic resonance 
imaging (MRI), and ultrasound/CT, have recently become 
available.80 Cancer diagnosis clearly benefits from these 
techniques due to multimodality, as a single agent may avoid 
the administration of multiple doses. However, the choice of 
imaging modality must be carefully considered since each 
one has its own advantages and limitations (ie, modalities 
with high sensitivity may have poor resolution).
AuNPs can be easily functionalized with additional 
imaging agents, and improvement in AuNP-based imaging 
systems may allow the observation of tissues not only on 
its basic anatomic configuration but also on the molecular 
level.42,81,82 Moreover, the real-time noninvasive monitoring 
potentially enables a rapid decision on whether the treatment 
regimen is effective in a given patient.40,83
Recently, Zhao et al84 have synthesized gold nanospheres 
doped with 199Au atoms using a one-step procedure for 
single-photon emission CT (SPECT)/CT imaging in an 
orthotopic mouse xenograft of triple-negative breast cancer 
(TNBC). The high-stable radiolabeling ability resulted from 
the incorporation of 199Au atoms into the crystal lattice of 
AuNPs. In addition, the 199Au-doped AuNPs were further 
modified with 1) PEGylation for favorable pharmacokinet-
ics and 2) d-Ala1-peptide T-amide (DAPTA) for targeting 
C–C chemokine receptor 5 (CCR5, a prognostic biomarker 
for breast cancer progression).84 Results demonstrate the 
suitability of 199Au for SPECT/CT imaging and the poten-
tial of 199Au-AuNP-PEG-DAPTA for accurately detecting 
CCR5 in vivo.
Moreover, He et al85 have recently synthesized novel 
AuNPs for magnetic and CT dual-mode imaging in a mouse 
xenograft of colorectal cancer. Fe
2
O
3
 was first coated with Au 
nanoshell (Fe
2
O
3
/AuNPs), and subsequently the surface of 
the Fe
2
O
3
/AuNPs was modified with lectins (sugar-binding 
proteins specifically bind to the carbohydrate moieties of 
the glycans on colorectal cancer cells) through bifunctional 
PEG-N-hydroxysuccinimide ester disulfide linkers (lectin–
PEG–Fe
2
O
3
/AuNPs). The lectin–PEG–Fe
2
O
3
/AuNPs demon-
strated long circulation time, site-specific tumor distribution, 
and high-quality MRI and CT contrast enhancement effects 
in tumor tissues, suggesting that the resultant AuNPs are a 
promising contrast agent for dual-mode MRI/CT colorectal 
cancer imaging.
Furthermore, selected examples of AuNP-based systemic 
cancer imaging are provided in Table 1, including the types 
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Table 1 A summary of studies on the in vivo use of gold nanocomplexes in systemic cancer imaging
Functional ligand Cancer type In vivo model Imaging technique Comment Reference
Gold nanospheres
Stabilizing ligand: PeG 
and PeI
Targeting ligand: FA
Papilloma (KB cells) S.C. xenograft 
mouse
CT The AuNP-PEI was modified with FA-linked 
PeG, forming FA-targeted PeGylated AuNPs. 
The resultant targeted AuNPs presented 
potential role as a nanoprobe for CT imaging of 
FA receptor-overexpressing xenografted tumor
77
Stabilizing ligand: PeG
fluorescent dye
Colon carcinoma 
(CT26 cells)
S.C. allograft 
mouse
CT The signal intensity and nanoprobe 
accumulation of Au-NPAPF-PeG in the 
tumor were up to 24 h post i.v. injection, 
suggesting the role as a promising nanoprobe 
for in vivo tumor-targeted CT imaging
87
Stabilizing ligands: PeG 
and glucose
Targeting ligand: glucose
Melanoma 
(SKMeL23 cells)
S.C. xenograft 
mouse
CT The AuNP-labeled T cells were injected 
intravenously to mice-bearing human melanoma 
xenografts, and whole-body CT imaging allowed 
examination of the distribution, migration, and 
kinetics of T cells
88
Stabilizing ligand: PeG Lung cancer (SPC-
A1 cells)
S.C. xenograft 
mouse
CT Results suggest that PeGylated AuNPs can 
be used as a promising contrast agent with 
enhanced biocompatibility for CT imaging in 
cancer diagnosis
89
Hybrid formulation: 
mesoporous silica NPs
emitter: 64Cu
Lung cancer Urethane-
induced lung 
cancer mouse
PeT 64Cu-labeled gold/mesoporous silica hybrid 
NPs can successfully detect the existence of 
clinically relevant spontaneous lung tumors in 
a urethane-induced lung cancer mouse model 
through PeT imaging
90
Stabilizing ligand: PeG
Targeting ligand: TAT
emitter: Gd3+
Glioblastoma (U87 
cells)
Orthotopic 
xenograft 
mouse
MRI Compared with the Gd3+ chelate, TAT-Au 
NP-Gd conjugates showed a 2.2-fold higher 
relaxivity and 82-fold enhancement in 
Gd3+ cellular uptake, which allowed for sensitive 
detection of the cancer cells via MRI
91
Stabilizing ligand: PeG
Targeting ligand: RGD
emitter: 125I
Glioblastoma (U87 
MG cells)
S.C. xenograft 
mouse
SPeCT/CT In vivo SPeCT/CT imaging results showed that 
the 125I-labeled RGD–PeG–AuNP probes can 
target the tumor site as soon as 10 min after 
injection
92
Stabilizing ligand: PeG
Targeting ligand: 
DAPTA
TNBC (4T1 cells) Orthotopic 
allograft mouse
SPeCT/CT The synthesis of AuNPs was doped with 199Au 
atoms into the crystal lattice of each AuNP, 
which ensured the highest possible stability for 
the radiolabel. when conjugated with DAPTA 
for the CCR5 receptor, the targeted AuNPs 
resulted in the in vivo sensitive and specific 
detection
84
Stabilizing ligand: GC
MMP sensitive linker: 
MMP peptide
NIR dye: Cy5.5
Colorectal cancer 
(HT-29 cells)
S.C. xenograft 
mouse
CT
NIR fluorescence 
imaging
The quenched Cy5.5 was recovered by cleavage 
of the peptide substrates upon exposure to the 
active MMPs, which is overexpressed in tumor 
tissue. As a result, the AuNPs simultaneously 
provided CT images with high spatial resolution 
and optical images with high sensitivity
93
Stabilizing ligand: PeG
Targeting ligand: FA
emitter: Gd3+
Papilloma (KB cells) S.C. xenograft 
mouse
CT
MRI
With the modification of PEG and the FA-
targeting ligand, the multifunctional AuNPs 
were able to be used for dual-mode CT/MRI 
of xenograft tumor models overexpressing FA 
receptors
94
Photostability enhancer: 
PB
Colon 
adenocarcinoma 
(HT-29 cells)
S.C. xenograft 
mouse
PAI
CT
The AuNPs were coated with PB to form the 
core/shell Au@PB NPs, which were found to be 
an excellent photoabsorbing agent for both PTT 
and PAI. The gold core ensured a remarkable 
contrast enhancement for CT imaging
95
(Continued)
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Table 1 (Continued)
Functional ligand Cancer type In vivo model Imaging technique Comment Reference
Stabilizing ligand: PeG
NIR dye: Cy5.5
Squamous 
carcinoma 
(SCC7 cells)
S.C. allograft 
mouse
PAI
NIR fluorescence 
imaging
The resultant AuNPs showed high fluorescence 
and PAI signals in the tumor over time, which 
peaked at the 6 h time point (tumor-to-normal 
tissue ratio of 3.64±0.51 for optical imaging and 
2.5±0.27 for PAI)
96
GNRs
Stabilizing ligand: PeG
Targeting ligand: biotin
Squamous 
carcinoma 
(SCC7 cells)
S.C. allograft 
mouse
PAI Under the photothermal/photoacoustic imaging, 
the in vivo pharmacodynamic effect of resultant 
GNRs could be monitored by precisely 
controlling the irradiation time and intensity of 
the NIR light
97
Amphiphilic ligands: 
PeG and PLGA
Glioblastoma 
(U87 MG cells)
S.C. xenograft 
mouse
PAI Amphiphilic AuNRs were prepared by grafting 
with PeG and PLGA forming vesicles. enhanced 
PA signals were due to the strong plasmonic 
coupling of the gold in the vesicular shell
73
Stabilizing ligand: PeG
Targeting ligand: CeT
epithelial 
carcinoma 
(A431 cells)
S.C. xenograft 
mouse
NIR fluorescence 
imaging
The NIR absorption images showed that the 
relative total photon counts from targeted 
Au nanorods in tumor tissue at 6 h were 
10-fold higher than those from nontargeted 
counterparts
68
Stabilizing ligand: PeG
NIR dye and 
photosensitizer: AlPcS4
Squamous 
carcinoma 
(SCC7 cells)
S.C. xenograft 
mouse
NIR fluorescence 
imaging
After i.v. injection of the AuNP–AlPcS4 complex, 
tumor sites were clearly identified on NIR 
fluorescence imaging as early as 1 h after 
injection
98
Stabilizing ligand: 
PNIPAAmMA
MRI contrast agents: 
Fe3O4 NPs
Glioma (C6 cells) S.C. xenograft 
mouse
PeT
PAI
GNRs were coated with PNIPAAmMA 
and Fe3O4 NPs using a simple LbL method, 
demonstrating the accurate tumor location 
using dual MRI and PAI
99
Stabilizing ligand: PeG
SeRS reporters
Ovarian cancer 
(MDA-435S, HeY, 
SKOv3 cells)
S.C. xenograft 
mouse
PAI
SeRS imaging
PeGylated Au nanorods allowed presurgical PAI 
visualization of a tumor for locoregional staging 
as well as intraoperative SeRS imaging for 
complete resection of tumor margins
100
Stabilizing ligand: 
liposome
Liver cancer 
(HepG2, Huh-7)
Orthotopic 
xenograft 
mouse
PAI
NIR fluorescence 
imaging
ICG-loaded liposome-Au nanorods exhibit 
favorable biocompatibility, high stability, and 
enhanced dual-model imaging signal
101
Gold nanoshells
Stabilizing ligand: 
PPAA shell
Targeting ligand: CeT
emitter: 89Zr
epithelial 
carcinoma (A431 
cells)
S.C. xenograft 
mouse
PeT PeT studies showed that the resultant 
AuNPs–PPAA–CeT–89Zr provided high tumor-
to-background ratio, suggesting a valuable tool 
for theranostic purposes
102
Stabilizing ligand: PeG
emitter: 64Cu
Head and neck 
squamous cell 
carcinoma (SCC4 
cells)
S.C. xenograft 
rat
PeT/CT The in vivo distribution of 64Cu-Au nanoshells 
was monitored using PeT/CT imaging at various 
time points after i.v. injection
103
Targeting ligand: lectin
MRI contrast agents: 
Fe3O4 NPs
Colorectal cancer 
(Sw620 cells)
S.C. xenograft 
mouse
MRI
CT
The lectin–Fe2O3@Au nanoshells showed great 
potential for dual-mode MRI and CT imaging of 
colorectal cancer in vivo
85
Targeting ligand: 
antibody (anti-NGAL)
MRI contrast agents: 
Fe3O4 NPs
Pancreatic cancer 
(AsPC-1 cells)
S.C. xenograft 
mouse
MRI
NIR fluorescence 
imaging
Antibody-conjugated Au nanoshells 
specifically targeted pancreatic cancer 
cells in vivo providing contrast for both NIR 
fluorescence and T2-weighted MRI with high 
tumor contrast
104
Stabilizing ligand: PeG
emitter: Gd3+
Melanoma (B16-
F10 cells)
S.C. xenograft 
mouse
MRI
X-ray imaging
Optical imaging
The Gd3+-conjugated Au-silica nanoshells 
showed great potential for multimode MRI, 
X-ray imaging, and optical imaging of melanoma 
in vivo
105
(Continued)
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Table 1 (Continued)
Functional ligand Cancer type In vivo model Imaging technique Comment Reference
MMP-triggering ligand: 
gelatin
MRI contrast agent: 
Fe3O4
Hepatoma (H22 
cells)
S.C. allograft 
mouse
CT and PAT imaging 
and MRI
A bio-eliminable MPNA, assembled from Fe3O4 
nanocluster and gold nanoshell, could respond 
to the local microenvironment with acidic pH 
and enzymes in tumors, collapse into small 
molecules and discrete NPs, and finally be 
cleared from the body
106
Gold nanoclusters
Stabilizing ligand: BSA
Targeting ligand: 
methionine
NIR dye: hydrophilic 
ICG
Breast cancer 
(MDA-MB-231 
cells)
S.C. xenograft 
mouse
NIR fluorescence 
imaging
The fluorescence signal in receptor-positive 
tumor was distinguishable from the normal 
tissues at 2 h post injection, reached peak 
intensity at 10 h post injection, and was still 
detectable at 96 h
107
Stabilizing ligand: BSA
Targeting ligand: FA 
and HA
Liver cancer 
(HepG2 cells)
Adenocarcinoma 
(A549 cells)
S.C. xenograft 
mouse
NIR fluorescence 
imaging
The strong fluorescence was observed at 
the tumor sites derived from the selectively 
accumulated targeted AuNPs, demonstrating a 
promising probe for the cancer diagnosis
108
Stabilizing ligand: BSA
Nuclear imaging moiety: 
Hoechst
Pancreatic tumor 
(MiaPaca-2 cells)
S.C. xenograft 
mouse
Maestro™ 2 in vivo 
imaging system
The in vivo imaging was performed via blue and 
red channels which displayed the accumulation 
of Hoechst-AuNCs mainly in the tumor and 
partly in the liver and kidneys
109
Stabilizing ligand: PeG
emitter: 64Cu
Prostate cancer 
(PC3 cells)
S.C. xenograft 
mouse
PeT/CT PeT/CT results demonstrated the 
heterogeneous intratumoral distribution of 
64CuAuNCs-PeG350 and 64CuAuNCs-PeG1000
110
emitter: 64Cu Glioblastoma 
(U87 MG cells)
S.C. xenograft 
mouse
PeT
IvIS® imaging system
64Cu-dopped AuNCs showed satisfactory 
synergistic dual-modality PeT and self-
illuminating NIR tumor imaging
111
Stabilizing ligand: BSA
emitter: Gd3+
Breast cancer 
(MCF-7 cells)
S.C. xenograft 
mouse
CT
NIR fluorescence 
imaging
MRI
The hybrid gold–gadolinium nanoclusters 
provided a promising nanoprobe for cancer-
targeted imaging and diagnosis in vivo
112
Stabilizing ligand: 
hairpin-DNA
Melanoma 
(M14 cells)
S.C. xenograft 
mouse
NIR fluorescence 
imaging
The hairpin-DNA-modified NaYF4@SiO4-Au 
promoted simultaneous deep tissue imaging 
and drug molecule release when combining 
single-band anti-stokes NIR emission and the 
photothermal effect
113
pH-sensitive ligand: 
azide and alkyne 
functionalities
Glioma 
(U87MG cells)
Orthotopic 
xenograft 
mouse
MRI and SeRS 
imaging
Multifunctional AuNPs could not only 
preoperatively define orthotopic glioblastoma 
xenografts by MRI with high sensitivity and 
durability in vivo but also intraoperatively 
guide tumor excision with the assistance of a 
handheld Raman scanner
114
Hollow AuNPs
Stabilizing ligand: PeG Adenocarcinoma 
(A549 cells)
S.C. xenograft 
mouse
CT The attenuation coefficient of hollow 
AuNPs is 5.3 times higher than that of the 
iodine-based contrast agent at the same 
concentration, demonstrating the potential of 
hollow AuNPs for CT imaging
115
Stabilizing ligand: PeG
Targeting ligand: RGD
emitter: 64Cu
Liver carcinoma 
vX2 tumor)
Orthotopic 
allograft rabbit
PeT/CT PeT/CT images showed that the 64Cu-RGD-
PeG-HAuNS showed higher tumor uptake than 
control groups at 24 h post injection
116
Stabilizing ligand: PeG
Targeting ligand: RGD
emitter: 64Cu
Glioblastoma 
(U87 cells)
Orthotopic 
xenograft 
mouse
PeT/CT
PAI
The dual-modality PAI and PeT/CT imaging 
provided a promising targeted AuNP-mediated 
glioma therapy
117
Gold nanostars
Stabilizing ligand: PeG
Raman reporter: 
p-mercaptobenzoic acid
Primary soft-tissue 
sarcomas
Transgenic 
mouse
CT
Two-photon 
luminescence 
imaging
The CT and optical results showed that 30 nm 
nanostars have higher tumor uptake, as well as 
deeper penetration into tumor interstitial space 
compared with 60 nm counterparts
118
(Continued)
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Table 1 (Continued)
Functional ligand Cancer type In vivo model Imaging technique Comment Reference
Stabilizing ligand: PeG Breast cancer 
(4T1 cells)
S.C. allograft 
mouse
PAI Novel Fe2O3@Au core/shell magnetic gold 
nanoflowers were synthesized through 
interactive growth of Au on Fe2O3 NPs. The 
nanoflowers exhibited remarkable SERS 
enhancement
119
emitter: Gd3+ Adenocarcinoma 
(A549 cells)
S.C. xenograft 
mouse
MRI, CT, and NIR 
fluorescence imaging
The existence of Gd3+ ions on GNCNs exhibits 
significant luminescence intensity enhancement 
for NIR fluorescence imaging, high X-ray 
attenuation for CT imaging, and reasonable r1 
relaxivity for MRI
120
SeRS labeling ligand: 
DTNB
Ovarian cancer 
(SKOv3)
S.C. xenograft 
mouse
Raman spectroscopy The SeRS Au nanostars were developed as 
a highly sensitive contrast agent for tumor 
detection in xenografted mice
121
Gold nanocages
Stabilizing ligand: PeG
emitter: 64Cu
Breast cancer 
(eMT-6 cells)
S.C. xenograft 
mouse
PeT/CT PeT/CT images clearly showed rapid localization 
of the 64Cu -PeG-Au nanocages in tumor at 1 h 
post injection with the administration of a trace 
amount
122
Gold nanoprisms
Stabilizing ligand: PeG Colorectal cancer 
(HT-29 cells)
S.C. xenograft 
mouse
PAI PeGylated Au nanoprisms showed the capacity 
to penetrate tumors and provided a high-
resolution signal amplifier for optoacoustic 
imaging
123
Gold nanotripods
Stabilizing ligand: PeG
Targeting ligand: RGD
Glioblastoma (U87 
MG cells)
S.C. xenograft 
mouse
PAI i.v. injection of RGD-conjugated Au-tripods 
showed PAI contrasts in tumors up to threefold 
higher than for the blocking group (coinjection 
with RGD)
124
Abbreviations: AIe, aggregation-induced emission; AuNPs, gold NPs; BSA, bovine serum albumin; CeT, cetuximab; CT, computed tomography; DAPTA, d-Ala1-
peptide T-amide; DTNB, 5,5-dithio-bis-(2-nitrobenzoic acid); FA, folic acid; GC, glycol chitosan; GNRs, gold nanorods; HA, hyaluronic acid; ICG, indocyanine green; i.v., 
intravenous; LbL, layer-by-layer; MMP, matrix metalloproteinase; MPNA, magnetoplasmonic nanoassembly; MRI, magnetic resonance imaging; NGAL, neutrophil gelatinase-
associated lipocalin; NIR, near-infrared; NPs, nanoparticles; PAI, photoacoustic imaging; PB, Prussian blue; PeG, polyethylene glycol; PeI, polyethylenimine; PeT, positron 
emission tomography; PLGA, poly(lactic-co-glycolic acid); PPAA, plasma-polymerized allylamine shell; PTT, photothermal therapy; SPeCT, single-photon emission CT; S.C., 
subcutaneous; SeRS, surface-enhanced Raman spectroscopy; TAT, transactivator of transcription; TNBC, triple-negative breast cancer.
of AuNPs, functional ligands, cancer types, in vivo animal 
models, imaging techniques, and end point comments.
AuNPs for cancer phototherapy
PTT
In addition to the aforementioned enhanced light scattering 
(referred as a radiative property) useful for optical imaging, 
AuNPs can also convert the absorbed light into heat via a series 
of nonradiative processes.86,125–129 Two main processes occur 
based on the heat energy contents: 1) the heat from the energy 
transformation is passed to the surrounding medium via the 
phonon–phonon relaxation within ~100 ps and 2) a competi-
tive process takes place between the heating by the electrons 
and the cooling by the surrounding medium, and when the 
heating rate is much faster than the cooling rate, AuNPs 
are melted in hundreds of femtoseconds.125–128 To facilitate 
cancer PTT, the first process has to dominate, and therefore, 
continuous-wave (CW) lasers that overlap maximally with 
the AuNP SPR absorption band need to be utilized.130,131
PTT can be achieved using gold nanospheres under the 
stimulation of pulsed or CW visible lasers due to the SPR 
absorption in the visible region, whereby such treatment is 
suitable for shallow tumors (ie, skin cancer).132,133 Recently, 
antibody-targeted gold nanospheres were developed to 
specifically target the EGFR on squalors carcinoma cells, 
and following stimulation by single 10 ns laser pulses 
at visible wavelengths, the resultant AuNPs generated 
intracellular photothermal micro bubbles and induced PTT 
for tumor inhibition in a subcutaneous cancer model.134
To treat tumors under the skin, NIR-active PTT is 
favorable as the light can penetrate more deeply due to the 
minimal absorption of the hemoglobin and water in tissues 
in this spectral region. Therefore, it is important to tune the 
SPR absorption of AuNPs to the NIR region by means of 
altering the shape, morphology, and structure, as described 
in the “Optical characteristics of AuNPs” section.
Recently, RGD-conjugated dendrite-modified GNRs 
(RGD-diners) were developed by Li et al135 for selective 
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tumor targeting and PTT in xenografted mice. At 6 h after 
intravenous injection, the resultant AuNPs accumulated 
inside tumor tissues via targeting the α
V
β
3
 overexpressed 
on cancer cells, and when it was irradiated with a NIR laser 
with a wavelength of 808 nm at a power density of 24 W/cm2 
(~0.5 cm diameter illuminated region), tumor growth was 
significantly reduced by RGD-diners in comparison with 
the control groups.
In addition, polymeric per fluorocarbon Nan capsules 
were prepared using the oil-in-water emulsion method, 
followed by the addition of PEGylated gold nanoshells on 
the surface.136 These resultant Nan capsules could not only 
enhance the contrast for ultrasound/CT imaging but also 
function as photo-absorbers for NIR-active PTT in xeno-
grafted mice.136
Recently, Ayala-Orozco et al137 have developed novel gold 
nanomatryoshkas composed of concentric gold–silica–gold 
layers and PEG-stabilizing ligands, for PTT of TNBC. 
In comparison with ~150 nm conventional silica–Au 
nanoshells, the resultant gold nanomatryoshkas (,100 nm) 
facilitated higher accumulation in tumors due to better pene-
tration of smaller AuNPs into tissue via the EPR effect. Under 
irradiation with a CW laser emitting 3 W/cm2 at a wavelength 
of 808 nm (~1.2 cm diameter illuminated region), the sur-
vival rate of an advanced TNBC model with .1,000 mm3 
tumors was significantly improved by gold nanomatryosh-
kas relative to conventional silica–Au nanoshells.137
Photodynamic therapy (PDT)
When photosensitizers are stimulated under the light of spe-
cific wavelengths, they convert the surrounding oxygen into 
toxic reactive oxygen species (ie, singlet oxygen) that may 
destroy malignant cells in surrounding proximity, which is 
now known as cancer PDT.138 However, most of the organic 
photosensitizers are only activated by UV and visible lights, 
which have poor tissue penetration and therefore are limited 
to the treatment of surface tumors.139 In addition, organic 
photosensitizers possess low molar extinction coefficients 
and therefore can undergo photobleaching and enzymatic 
degradation.139 In contrast, metal nanostructures (ie, gold, 
silver, and platinum) can overcome these limitations, as 
they possess 5–6 orders of molar extinction coefficients, 
better photostability, and enhanced resistant to enzymatic 
degradation.140
To tackle the treatment of deeply buried tumors, AuNPs 
that are able to exert PDT upon NIR light activation 
have recently been developed. For example, lipid-coated 
gold nanocages were produced to activate PTT and PDT 
simultaneously in melanoma-xenografted mice.141 Following 
direct injection of lipid-coated gold nanocages into the tumor 
site, a 980 nm CW laser (150 mW/cm2; 10 min) was used 
to stimulate AuNPs, which raised temperature (~10°C) and 
generated the singlet oxygen. As a result, this treatment 
significantly inhibited tumor growth in comparison with an 
irradiation of the 808 nm diode laser (150 mW/cm2; 12 min; 
only PTT was induced in this wavelength).
In addition, a variety of organic photosensitizers with 
NIR-active property can also be incorporated into AuNPs for 
PDT with a low dose of organic photosensitizers and short 
exposure of laser irradiation. For example, indocyanine green 
(ICG, a medical diagnostic agent) is used to produce singlet 
oxygen for PDT.142 Recently, GNR/ICG-loaded chitosan 
nanospheres (CS-AuNR-ICG NSs) were prepared by the non-
solvent counterion complexation method and electrostatic 
interaction.142 The CS-AuNR-ICG NSs could effectively load 
ICG and protect it from rapid hydrolysis. Results of in vivo 
NIR fluorescence imaging and biodistribution showed that 
these Au-chitosan NPs could be specifically delivered to 
the tumor site. Under an 808 nm laser, CS-AuNR-ICG NSs 
simultaneously produced hyperthermia and reactive oxygen 
species, which achieved complete inhibition of tumor growth 
in xenografted mice. Compared with PTT (GNRs) or PDT 
(ICG) alone, the combined therapy showed a significantly 
improved therapeutic efficacy.142
In addition, selected examples of AuNP-based cancer 
phototherapy are provided in Table 2, including the types 
of AuNPs, functional ligands, cancer types, in vivo animal 
models, laser types, and end point comments.
Barriers to the translation of AuNPs 
for cancer theranostics
Although local administration of therapeutics has demon-
strated significant potential for the treatment of shallow 
cancers (ie, skin cancer and head and neck cancer) due to 
the ease of access, many diseases (eg, metastatic cancers) 
still require systemic administration of therapeutic agents 
into the bloodstream. In this section, major challenges, 
namely, 1) instability in the blood circulation, 2) targeting 
to specific cells of interest, and 3) activation in response to 
the tumor microenvironment (TME),174 for systemic AuNP 
delivery in terms of cancer diagnosis and phototherapeutics 
are discussed (Figure 2).
Blood circulation
It has been reported, following intravenous administra-
tion, that rapid glomerular filtration occurs in the case 
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Table 2 A summary of studies on the in vivo use of gold nanocomplexes in systemic cancer PTT and PDT
AuNP type Functional ligand Cancer type In vivo model Laser Comment Reference
PTT
Au nanorods Stabilizing ligand: PeG Melanoma (MDA-
MB-435 cells)
S.C. xenograft 
mouse
810 nm laser
2 w/cm2
5 min
A single i.v. injection of PeG-Au nanorods 
enabled destruction of the irradiated 
human xenograft tumors in mice
143
Au nanorods Stabilizing ligand: PeG
Targeting ligand: 
RGD
Glioblastoma (U87 
MG cells)
S.C. xenograft 
mouse
808 nm laser
1 w/cm2
10 min
Au nanorods showed high tumor-targeting 
ability via receptor-mediated pathway and 
were successfully used for PTT
144
Au nanorods Coating material: 
silica
Breast cancer (4T1 
cells)
S.C. allograft 
mouse
808 nm laser
4 w/cm2
10 min
when Au nanorods were stimulated 
with the NIR laser, DOX was released 
for synergistic therapeutic effect in 
combination with PTT
145
Au nanorods Stabilizing ligand: PeG 
and dendrimers
Colon carcinoma 
(26 cells)
S.C. allograft 
mouse
808 nm laser
0.24 w/cm2
10 min
The combined photothermal-chemo 
treatment using AuNPs containing DOX 
for synergistic PPT and chemotherapy 
exhibited higher therapeutic efficacy than 
either single treatment alone
146
Au nanorods Coating materials: 
PvP and AgNO3
Targeting ligand: 
aptamer
Adenocarcinoma 
(A549 cells)
S.C. xenograft 
mouse
980 nm laser
0.84 w/cm2
5 min
The resultant AuNPs specifically 
accumulated into tumor tissues and 
induced PTT for dramatically stronger 
antitumor effect upon NIR laser irradiation
147
Au nanorods Au nanorods 
encapsulated in 
CHI/sodium ALG 
microcapsules
Breast cancer 
(4T1 cells)
S.C. allograft 
mouse
808 nm laser
3.83 J/cm2
5 min
Self-assembled Au nanorods in bilayer-
modified microcapsules localized at tumor 
sites, generated vapor bubbles under NIR 
exposure, and subsequently damaged 
tumor tissues
148
Au nanorods Stabilizing ligand: PeG
Targeting ligand: 
antibody for 
anaerobic bacteria 
(C. difficile)
Adenocarcinoma 
(A549 cells)
S.C. xenograft 
mouse
808 nm laser
0.5 w/cm2
10 min
The C. difficile spores was i.v. injected 
for 2 days, followed by the injection of 
antibody-Au nanorods to specifically target 
the germination of the C. difficile spores 
in tumor tissues (low level of oxygen 
microenvironment). Under the NIR laser, 
antibody-Au nanorods completely inhibited 
tumor growth
149
Au nanorods Stabilizing ligand: 
dendrimer
Non-small-cell lung 
cancer (PC-9 cells)
S.C. xenograft 
mouse
808 nm laser
3.6 w/cm2
8 min
Dendrimer-stabilized Au nanorods 
(DSAuNRs, sub-10 nm in length) showed 
significantly enhanced absorption in the 
NIR region compared with dendrimer-
stabilized Au nanospheres. The tumor 
growth was significantly retarded by the 
photothermal efficiency of DSAuNRs
150
Au nanorods Coating material: 
silica
Targeting ligand: 
antibody for CXCR4
Gastric cancer 
(MGC803 cells)
S.C. xenograft 
mouse
808 nm laser
1.5 w/cm2
3 min
iPS cells were transfected with the 
resulted AuNRs@SiO2@CXCR4 
via receptor-mediated pathway. The 
transfected iPS cells were homing to 
tumor tissues, and the tumor growth 
was significantly slowed down by the 
photothermal efficiency of AuNRs@
SiO2@CXCR4
151
Au nanoshells Multilayered AuNPs 
with silica and gold, 
also termed Au 
nanomatryoshkas
Breast cancer 
(MDA-MB-231 cells)
Orthotopic 
xenograft mouse
810 nm laser
2 w/cm2
5 min
Au nanomatryoshkas exhibited improved 
PTT efficacy when compared with 
conventional gold nanoshells
152
Au nanoshells Stabilizing ligand: PeG Breast cancer 
(4T1 cells)
S.C. allograft 
mouse
808 nm laser
1 w/cm2
10 min
In combination with chemotherapeutics, 
the resultant Au nanoshells achieved 
complete destruction of the tumors at a 
low laser irradiation without weight loss 
or recurrence of tumors
153
(Continued)
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Table 2 (Continued)
AuNP type Functional ligand Cancer type In vivo model Laser Comment Reference
Au nanoshells Stabilizing ligand: PeG
Inner core: PLGA 
NPs
Glioblastoma (U87 
MG cells)
S.C. xenograft 
mouse
808 nm laser
1.5 w/cm2
1.5 min
The temperature of tumor treated with 
the resultant Au nanoshells was rapidly 
increased to 46.6°C, which released 
DOX for synergistic therapeutic effect in 
combination with PTT
154
Au nanoshells Stabilizing ligand: PeG
Inner core: PeI-PAsp 
(DIP/MeA) NPs
Liver cancer 
Bel-7402 cells
S.C. xenograft 
mouse
808 nm laser
1.5 w/cm2
2 min
A polymeric vesicle encapsulating DOX 
was prepared and then decorated with a 
gold layer using a modified method of in 
situ gold seed growth. The NIR light energy 
was converted into heat, which killed 
cancer cells in the vicinity and induced 
the rupture of nanoshell to release DOX 
inside tumor
155
Au nanoshells Stabilizing coating: 
MPCMs
Inner core: silica
Breast cancer 
(4T1 cells)
S.C. allograft 
mouse
808 nm laser
1 w/cm2
5 min
MPCM-coated Au nanoshells presented 
longer blood circulation and tumor 
accumulation in a xenograft mouse model 
of breast cancer. Tumor growth was 
significantly slowed down by irradiation of 
NIR laser
156
Au nanostars Stabilizing ligand: PeG
Targeting ligand: 
RGD
Glioblastoma 
(U87 MG cells)
S.C. xenograft 
mouse
790 nm laser
1 w/cm2
10 min
RGD-Au nanostars were designed to 
specifically target overexpressed integrin 
αvβ3 on tumor neovasculature, enabling 
highly sensitive PTT
157
Au nanostars Surface coating: 
organosilica
Breast cancer 
(MDA-MB-231 cells)
S.C. xenograft 
mouse
808 nm laser
0.5 w/cm2
5 min
In 5 min of irradiation, the temperature 
at the tumor region of mice treated with 
Au nanostars increased remarkably to 
about 57°C
158
Au nanocages Targeting ligand: HA Breast cancer 
(MDA-MB-231 cells)
S.C. xenograft 
mouse
808 nm laser
1 w/cm2
5 min
HA-coated Au nanocages accumulated 
inside tumor tissues via HA-CD44 
interaction. Under the NIR stimulation, 
HA-coated Au nanocages significantly 
slowed down the tumor growth. In 
addition, a complete tumor inhibition 
was achieved when combined with 
chemotherapy
159
Au nanocages Gold surface was 
coated with PvP and 
RBC membranes
Breast cancer 
(4T1 cells)
S.C. allograft 
mouse
850 nm laser
1 w/cm2
10 min
RBC-AuNCs exhibited significantly 
enhanced in vivo blood retention and 
circulation lifetime. with NIR laser, 
RBC-AuNCs achieved 100% survival 
of tumor-bearing mice over a span of 
45 days
160
Hollow Au 
nanospheres
Stabilizing ligand: PeG
Targeting ligand: 
a peptide (TNYL)
Ovarian carcinoma 
(SKOv3 cells)
S.C. xenograft 
mouse
808 nm laser
1.5 w/cm2
3 min
Under NIR laser irradiation, the resultant 
hollow Au nanospheres induced PTT for 
dramatically stronger antitumor effect 
against ephB4-positive tumors than ephB4-
negative tumors
161
Hollow Au 
nanospheres
Stabilizing ligand: PvP 
and citrate
Ovarian carcinoma 
(SKOv3 cells)
S.C. xenograft 
mouse
808 nm
3.0 w/cm2
10 min
The resultant AuNPs exhibited a 
significantly enhanced surface plasmon 
absorption in the NIR region, inducing 
an efficient photothermal conversion and 
stronger anticancer ability under NIR laser 
irradiation
162
Au 
nanoclusters
A pH-sensitive 
ligand inducing Au 
nanoclusters in mild 
acidic environments
Fibrosarcoma 
(HT-1080 cells)
S.C. xenograft 
mouse
660 nm laser
0.5 w/cm2
1 min
MSCs were first transfected with the 
resultant AuNPs. The MSC-AuNPs 
showed a 37-fold higher tumor-targeting 
efficiency and resulted in a significantly 
enhanced anticancer effect upon 
irradiation
163
(Continued)
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Table 2 (Continued)
AuNP type Functional ligand Cancer type In vivo model Laser Comment Reference
Au 
nanoplates
Stabilizing ligand: PeG Breast cancer 
(4T1 cells)
S.C. allograft 
mouse
808 nm laser
0.5 w/cm2
10 min
PeGylated AuNPs presented good 
biocompatibility, prolonged blood 
circulation, and relatively high tumor 
accumulation. The NIR laser irradiation 
induced PTT and retarded tumor growth
164
PDT
Au 
nanospheres
Coating materials: 
heparin
Photosensitizer: PhA
Adenocarcinoma 
(A549 cells)
S.C. xenograft 
mouse
670 nm laser
3 mw/cm2
30 min
The PDT effects of PhA-H/AuNP 
significantly retarded tumor growth in 
comparison with PhA alone
165
Au nanorods Coating materials: 
silica and PeG
Photosensitizer: PPIX
Adenocarcinoma 
(HeLa cells)
S.C. xenograft 
mouse
532 nm laser
25 mw/cm2
15 min
A real-time and specific in vivo SERS and 
fluorescence detection method using the 
resultant AuNPs was applied for tumor 
detection and subsequent PDT
166
Au nanorods AuNPs encapsulated 
in Pluronic nanogel
Photosensitizer: Ce6
Squamous 
carcinoma 
(SCC7 cells)
S.C. allograft 
mouse
655 nm laser
20 J/cm2
30 min
A remarkable synergy for anticancer 
treatment was observed when PDT 
was applied before PTT, both 
in vitro and in vivo
167
Au nanorods Stabilizing ligand: PeG
Targeting ligand: FA
Melanoma
(B16F0 cells)
S.C. allograft 
mouse
915 nm
130 mw/cm2
15 min
GNRs alone can sensitize the formation 
of singlet oxygen and exert dramatic PDT 
effects on complete destruction of tumors 
in mice under light excitation
168
Au nanorods Stabilizing ligand: CHI
Photosensitizer: ICG
Liver cancer 
(H22 cells)
S.C. allograft 
mouse
808 nm laser
2 w/cm2
10 min
The resultant NPs have been successfully 
prepared to facilitate in vivo PDT resulting 
in abundant ROS produced by ICG under 
NIR irradiation
142
Au nanorods Stabilizing ligand: 
poly(allylamine 
hydrochloride)
Photosensitizer: RB
Oral squamous 
carcinoma
A carcinogen 
was topically 
injected into the 
left cheek pouch 
mucosa
532 nm 
green light
1.79 w/cm2
10 min
The PDT-only treatment achieved a 46.5% 
tumor inhibition rate; when combined with 
PTT effects under NIR laser stimulation, 
95.5% tumor inhibition rate was achieved
169
Au nanorods endosome disruptive 
ligand: Tat/HA2
Photosensitizer: 
AlPcS4
Adenocarcinoma 
(HeLa cells)
S.C. xenograft 
mouse
808 nm laser
400 mw/cm2
15 min and 
680 nm LeD 
light
10 mw/cm2
40 min
AuNRs absorbed an SPR wavelength 
(808 nm) and converted it into 
heat, causing the release of AlPcS4. 
Subsequently, upon illumination at 680 nm, 
the released AlPcS4 transferred the photon 
energy to oxygen molecules, stimulating 
ROS generation to slow down the 
tumor growth
170
Au nanocages Stabilizing ligand: PeG
Photosensitizer: 
HPPH
Colon cancer 
(Colon-26 cells)
S.C. allograft 
mouse
665 nm laser
75 mw/cm2
30 min
The tumor growth was suppressed due to 
the enhanced phototoxicity of the HPPH-
Au nanocages under the laser stimulation
171
Au 
nanoclusters
AuNPs encapsulated 
in silica
Photosensitizer: Ce6
Melanoma (MDA-
MB-435 cells)
S.C. xenograft 
mouse
671 nm laser
100 mw/cm2
10 min
The resultant AuNCs@SiO2–Ce6 
completely inhibited tumor growth in mice 
due to PDT effects when compared with 
Ce6 alone and AuNCs@SiO2 alone
172
Au quantum 
clusters
Stabilizing ligand: 
lipoic acid
Targeting ligand: FA
Photosensitizer: PPIX
Glioma (C6 cells) S.C. xenograft 
mouse
532 nm laser
1.5 w/cm2
15 min
Under the laser stimulation, singlet 
oxygen efficiency of the resultant NPs was 
significantly higher when compared with 
that of the PPIX alone
173
Abbreviations: ALG, alginate; AuNPs, gold NPs; C. difficile, Clostridium difficile; Ce6, chlorin e6; CHI, chitosan; DOX, doxorubicin; FA, folic acid; GNRs, gold nanorods; 
HA, hyaluronic acid; HPPH, 3-devinyl-3-(1′-hexyloxyethyl)pyropheophorbide; ICG, indocyanine green; iPS, Induced pluripotent stem; i.v., intravenous; LeD, light-emitting 
diode; MPCMs, macrophage cell membranes; MSCs, mesenchymal stem cells; NIR, near-infrared; NPs, nanoparticles; PDT, photodynamic therapy; PeG, polyethylene glycol; 
PeI, polyethylenimine; PeI-PAsp (DIP/MeA), polyethylenimine-b-poly(2-diisopropylamino/2-mercaptoethylamine) ethyl aspartate; PhA, pheophorbide a; PLGA, poly(lactic-co-
glycolic acid); PPIX, protoporphyrin IX; PTT, photothermal therapy; PvP, polyvinylpyrrolidone; RB, Rose Bengal; RBC, red blood cell; ROS, reactive oxygen species; S.C., 
subcutaneous; SeRS, surface-enhanced Raman spectroscopy; SPR, surface plasmon resonance.
of NPs with a hydrodynamic size of ,6 nm, while those 
with particle sizes of .8 nm are able to avoid kidney 
removal.175 While NPs with .10 nm diameter may reduce 
renal filtration, larger particles (ie, .100 nm) can evoke the 
reticuloendothelial system (RES).176 The RES, also known 
as the mononuclear phagocyte system (MPS), is part of the 
immune system, which primarily involves the liver, spleen, 
and lymph nodes.176,177 Foreign materials will be removed 
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Figure 2 Systemic delivery of multifunctional AuNPs for cancer bioimaging and phototherapeutics.
Notes: (1) Following intravenous injection into the blood, AuNPs with a particle size of ,6 nm are prone to glomerular filtration. (2 and 3) When blood proteins bind to 
AuNPs nonspecifically, the resultant complexes tend to be taken up by MPS for opsonization (a means of identifying the invading particle to the phagocyte). (4) Multifunctional 
AuNPs (~100 nm) with stealth coating materials, bioresponsive moieties, bioactive targeting ligands, and/or bioimaging agents can efficiently accumulate inside tumor tissues 
via the “EPR” effect and specifically target cancer cells via ligand–receptor pathway. (5) As a result, theranostic AuNPs can sensitively image the tumors and effectively induce 
PTT and/or PDT under the irradiation of the NIR light.
Abbreviations: AuNPs, gold nanoparticles; ePR, enhanced penetration and retention; MPS, mononuclear phagocyte system; NIR, near-infrared; PDT, photodynamic 
therapy; PTT, photothermal therapy; ROS, reactive oxygen species.
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out of the blood circulation by the immune cells in MPS, 
thus dramatically reducing the circulatory half-time (t
1/2
) of 
NPs.177 In addition, nonspecific adsorption of blood proteins 
onto the surface of NPs (ie, hydrophobic interactions between 
hydrophobic patches on proteins and hydrophobic ligands on 
NPs, and electrostatic interactions between anionic albumin 
and cationic NPs) may inhibit NPs’ targeting capabilities or 
increase the overall particle size of NPs, and eventually the 
resultant large complexes are either trapped in the capillary 
endothelium of the lung or taken up by MPS.176
The modification of stabilizing ligands (ie, PEG, block 
copolymers, and hyaluronic acid [HA]) onto the gold sur-
face, forming the so-called “stealth” particles capable of 
improving pharmacokinetic profiles, has been substantially 
reviewed previously.76,178,179 In addition to these stabilizing 
components, long-circulating NPs have also been developed 
where the NP surface is coated with the cellular membrane 
of red blood cells (RBCs) and leukocytes.150,154,174,175 As an 
alternative stealth coating material, the membrane of these 
cells completely covers the NP surface with their “self-
markers” (ie, proteins, glycans, and acidic sialyl moieties), 
and the resultant NPs, recognized as the host’s own cells, can 
actively evade the immune system. For example, Piao et al160 
reported that the RBC-coated gold nanocages exhibited 
longer blood retention compared with the PEGylated coun-
terparts. In addition, the fusion of RBC membranes over gold 
surface did not alter the unique porous and hollow structures 
of gold nanocages. Following systemic administration, the 
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RBC-coated gold nanocages demonstrated enhanced tumor 
accumulation, induced NIR-active PTT, and eventually 
achieved 100% survival of tumor-bearing mice over a span 
of 45 days.160
Targeting to specific cells of interest
It is known that tumor grows rapidly via a process termed 
angiogenesis (new blood vessels are developed from the 
preexisting vasculature).177,180 The porous vasculature of a 
tumor is known to provide access to blood-circulating par-
ticles with sizes ,500 nm, usually ,150 nm.176 In addition, 
the lymphatic drainage system of tumor tissues is normally 
underdeveloped, and thus, NPs may not be removed. This 
EPR effect will facilitate “passive” accumulation of NPs in 
tumor tissues. In addition, targeting ligands (ie, antibodies 
and peptides) can be functionalized on NPs for “active” 
cancer targeting. Taking advantage of the “passive” and 
“active” targeting, recent advances in the design of AuNPs 
have offered great potential for accurate diagnosis and tar-
geted therapy. For example, targeted gold nanocages were 
developed by coating with HA (a targeting ligand for CD44) 
on the gold surface to specifically recognize cancer cells over-
expressing CD44.159 The HA–Au nanocages containing DOX 
could be efficiently uptaken by a receptor-mediated process, 
and subsequently, the coated HA molecules were degraded in 
lysosomes, resulting in the release of DOX. Biodistribution 
results demonstrate that targeted gold nanocages achieved 
significantly higher tumor accumulation relative to nontar-
geted counterparts in tumor-bearing mice. As a result, HA-
coated gold nanocages containing DOX significantly slowed 
down the tumor growth, and more importantly, complete 
tumor inhibition was achieved when combined with PTT 
under the NIR stimulation.159
Activation in response to TMe
TME is specifically adapted to support the growth, inva-
sion, and metastasis of primary tumor tissues; this has been 
substantially reviewed previously.181 “Smart” bioresponsive 
NPs have been developed for targeted delivery and controlled 
drug release by exploiting the TME, where a slightly acidic 
environment, a low oxygen (hypoxia) niche, and overexpres-
sion of extracellular matrix (ECM) components (ie, MMPs) 
are evident.181
It is now known that the hypoxia region in solid tumors is a 
complex microenvironment with a low oxygen concentration 
and deficient nutrients.182 The hypoxic environment can not 
only lower the susceptibility of cancer cells to anticancer drugs 
but also reduce the response of cancer cells to free radicals.182 
Although the hypoxia of solid tumors causes a hurdle in 
therapy, the low level of oxygen microenvironment serves as 
an ideal habitat for a number of anaerobic bacteria. Recently, 
Luo et al149 reported a tumor-targeted AuNP delivery using 
two anaerobic bacterial strains, namely, Bifidobacterium 
breve UCC2003 and Clostridium difficile CCUG 37780. 
In this study, two approaches were designed for the active 
NP delivery: 1) a direct conjugation of GNRs on the sur-
face of the vegetative B. breve for intravenous delivery 
into hypoxic region (a cargo-carrying approach) and 2) the 
injection of the C. difficile spores first, followed by the intra-
venous administration of the antibody–GNR conjugates to 
specifically target the germination of the C. difficile spores 
(an antibody-guiding approach). Under NIR excitation, the 
antibody-directed strategy showed stronger imaging and 
achieved effective PTT to completely inhibit tumor growth 
in a subcutaneous mouse cancer model.149
In addition, Sun et al93 developed novel AuNPs for dual 
CT/optical imaging of cancer. First, AuNPs were modified 
with glycol chitosan (GC) polymers (GC-AuNPs) for excel-
lent stability and enhanced EPR effect. Second, fluorescent 
probes were chemically modified to GC-AuNPs via MMP-
active peptides (MMP-GC-AuNPs). The NIR fluorescent 
probes were strongly quenched by the combinational quench-
ing effects between the organic black hole quencher and the 
gold surface, but the quenched probes were reactivated upon 
exposure to MPPs in the TME. As a result, CT images with 
high spatial resolution and optical images with high sensitiv-
ity were simultaneously achieved using these AuNP-based 
CT/optical dual imaging probes.93
Biodistribution, metabolism, and 
nanotoxicity
In addition to tumor accumulation via the EPR effect, a 
majority of intravenously administrated NPs are nonspe-
cifically distributed into healthy tissues (ie, phagocytic 
cell-rich organs such as the liver and spleen) before the 
renal clearance.183 Although the gold core is generally inert, 
nontoxic, and biocompatible, significant toxicity of AuNPs 
can be induced by the synthesis method of gold nanostruc-
tures, physicochemical properties (ie, size, morphology, and 
surface charge), surface conjugates and ligands, the doses, 
and the administration routes.173 Recently, numerous studies 
have described AuNPs designed to investigate whether their 
in vivo behaviors such as accumulation in healthy tissues and 
renal clearance cause unwanted effects.184–187
For example, the glomerular filtration, biodistribution, 
and toxicity of glutathione (GSH)- and bovine serum albumin 
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(BSA)-capped AuNPs were evaluated using mice.188 As a result, 
smaller AuNPs (GSH-coated, ~2 nm) caused highly efficient 
kidney removal and were more readily metabolized relative to 
the larger AuNPs (BSA-coated, ~8 nm), suggesting that the tox-
icity was related to the size of AuNPs. In addition, although both 
AuNPs caused acute infection, inflammation, and kidney func-
tion damage after 24 h, these effects were eliminated for ~2 nm 
AuNPs after 28 days; in contrast, ~8 nm AuNPs further accumu-
lated in the liver and spleen causing irreparable toxicity.188
It has been difficult to substantially evaluate the biodis-
tribution, clearance, and toxicity of AuNPs, due to the fact 
that experimental designs are diverse, including the particle 
size, charge and shape, functionalization methods, types of 
animal models, delivery doses, and administration routes. 
Therefore, standard approaches are urgently needed in the 
future to facilitate development and approval of AuNPs for 
cancer theranostics.189
Conclusion and future perspectives
The newly emerging concept termed theranostics is well 
established as the development of novel strategies to com-
bine diagnostic and therapeutic capabilities into a single 
agent facilitating specific and personalized therapies for 
diseases.190 The rationale behind the concept is that diseases, 
such as cancers, are extremely heterogeneous, and all exist-
ing treatments are effective for only certain patients and 
at selective stages of disease development.191 Therefore, a 
combined approach of diagnostics and therapeutics may 
provide promising treatment protocols that are more specific 
to individuals, ie, personalized medicines, and therefore more 
likely to offer improved prognoses.
Recent advances in understanding the optical and chemical 
properties of gold have enabled the design of novel AuNPs 
containing diagnostic and therapeutic functions that can be 
integrated into one system.40,42,192 Au-nanocomplex-based 
cancer imaging and phototherapy are reviewed in the “AuNPs 
for cancer diagnosis” and “AuNPs for cancer phototherapy” 
sections, respectively (Tables 1 and 2); many of these Au 
nanocomplexes, by tuning the size, shape, and structure, and 
by using different functional ligands, are capable of improv-
ing sensitive cancer diagnosis and targeted phototherapy 
simultaneously, under the stimulation of the appropriate light 
resources (NIR light is preferred in most cases). In addition, 
a number of AuNP-based theranostics have advanced into 
clinical trials (NCT03020017, NCT01270139 NCT02755870, 
NCT01420588, and NCT02782026). For example, the safety 
evaluation of a drug named NU-0129 is now undertaking an 
early Phase I trial (NCT03020017). NU-0129 is composed of 
siRNA arranged on the surface of Au nanospheres, and when 
infused in patients with recurrent glioblastoma multiforme or 
gliosarcoma, the Au nanocomplexes can penetrate the blood–
brain barrier and deliver siRNA into tumor cells knocking down 
the expression of oncoprotein Bcl2Like12, which may result 
in significant inhibition of tumor growth (NCT03020017). 
Furthermore, CNM-Au8 (a drug candidate now being tested in 
clinical trial), an Au nanocrystal suspension drug, has recently 
been developed by Clene Nanomedicine (Salt Lake City, 
UT, USA) using Clean-Surface Nanosuspension™ (CSN) 
technology (it produces atomically clean-surface elemental 
nanocrystals, free of any residual surface chemicals, or surface-
capping agents) (www.clene.com). The oral administration of 
CNM-Au8 has demonstrated efficient immunomodulation in 
established demyelination animal models (www.clene.com). 
The safety, tolerability, and pharmacokinetics of CNM-Au8 are 
now under evaluation in healthy volunteers, with a hope of facil-
itating the application of the drug for the demyelinating disorder 
neuromyelitis optica (NMO) in the future (NCT02755870).
To overcome in vivo delivery barriers, Au nanocomplexes 
are normally modified with functional moieties such as 
stabilizing materials, targeting ligands, and bioresponsive 
linkers. However, it should be borne in mind that exten-
sive functional modifications may cause unwanted toxic 
side effects, and therefore, further investigation is required to 
quantify the benefit of a treatment versus the risk of toxicity 
before theranostic Au nanocomplexes can be translated into 
clinically accepted strategies for cancer therapy.
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